

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

eNLife Research secures Rs 6 Cr to advance AI-powered blood biomarker platform for detecting Alzheimer's disease

09 July 2026 | News

Funding will support the expansion of the company's research and development team in Bengaluru



eNLife Research, a Bengaluru-based deep tech startup incubated at Foundation for Science Innovation and Development (FSID), Indian Institute of Science, is building an affordable, AI-driven diagnostic platform for Alzheimer's disease (AD) and other neurodegenerative diseases.

The company has raised Rs 6 crore in a seed funding round led by Piper Serica VC Fund. The capital will be deployed to build and validate eNLife's blood-based biomarker platform, expand its Bengaluru-based R&D team, and take the company's first diagnostic assay from prototype to clinical-grade validation.

eNLife is working towards making early Alzheimer's detection accessible to patients in India years before conventional diagnostics can identify the disease.

The startup is developing a blood test that screens for a panel of 5 to 7 biomarkers linked to onset of AD like amyloid beta and detrimental forms of tau, the two hallmark proteins associated with Alzheimer's pathology. It is also designing next-generation assays capable of simultaneously tracking 25 to 100 biological markers to identify multiple forms of dementia and other neurodegenerative diseases years before the onset of clinical symptoms.

The company is currently collaborating with researchers associated with leading institutions, including the Indian Institute of Science (IISc), the National Institute of Mental Health and Neurosciences (NIMHANS), the Tata Institute of Fundamental Research (TIFR), Hyderabad, and the Centre for Brain Research (CBR), Bengaluru, to develop India-specific biomarker datasets.